Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LM-108 + Toripalimab vs Paclitaxel in 2L CCR8+ Advanced Gastric/GEJ Cancer
NCT07362186Phase 3Recruiting
- Sponsor
- LaNova Medicines
- Start
- Apr 2026
- Primary completion
- Aug 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of LM-108 in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by LaNova Medicines. Primary endpoint: Overall Survival at 42 months. Started Apr 2026; status: recruiting.
02
Drugs
LM-108
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07362186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07362186.